MDS Education
MDS management ranges from supportive care to hypomethylating agents and transplant consideration, with molecular profiling increasingly guiding decisions. Knowledge Med sessions help community providers navigate MDS risk stratification and treatment through interactive case simulations.
Non-promotional, independently reviewed sessions led by faculty from Johns Hopkins, Columbia, Mount Sinai, and other leading academic medical centers.
What Providers Navigate
Physicians managing myelodysplastic syndromes face evolving treatment decisions that interactive, independently reviewed education can help address.
- Applying IPSS-M molecular risk stratification to guide treatment intensity
- Optimizing hypomethylating agent therapy and monitoring response
- Managing transfusion dependence and iron overload
- Identifying transplant candidates and timing referral
What Sessions Cover
Knowledge Med MDS sessions use interactive case simulations to address these topics and more.
- IPSS-M and molecular risk stratification in MDS
- Lower-risk MDS: erythropoiesis-stimulating agents, luspatercept, and lenalidomide
- Higher-risk MDS: HMA therapy and emerging combinations
- Transplant decision-making and bridge strategies
Interactive MDS Sessions
Case Simulations
Work through realistic myelodysplastic syndromes patient cases with expert faculty, making treatment decisions at each stage.
Live Polling
See how your clinical decisions compare to peers in real time — revealing practice patterns and knowledge gaps.
Personalized Report
Receive a session summary with your individual responses, peer benchmarks, and key MDS clinical takeaways.
More Hematologic Malignancy Sessions
Knowledge Med offers interactive sessions across many indications — these are just some of the areas we cover.
Chronic Lymphocytic Leukemia
CLL / SLL — First-line therapy selection in CLL: BTK inhibitors vs venetoclax combinations
Diffuse Large B-Cell Lymphoma
DLBCL — Frontline DLBCL: pola-R-CHP and risk-adapted strategies
Multiple Myeloma
Frontline induction: triplet vs quadruplet therapy and transplant decisions
Acute Myeloid Leukemia
AML — Molecular-guided frontline therapy selection in AML
Join a MDS Session
Third-party, non-promotional myelodysplastic syndromes education led by faculty from leading academic medical centers. Case simulations. Live polling. Personalized insights.
Join a Session